Amneal Pharmaceuticals (AMRX) AI Stock Analysis

• Market Cap: $4.54B
• Dividend Yield: N/A
• Average Volume (3M): 2.83M
• Price to Earnings (P/E): 1040.1
• Beta (1Y): 0.85
• Revenue Growth: 9.50%
• EPS Growth: N/A
• Country: US
• Employees: 8,300
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.17
• Shares Outstanding: 314,362,900
• 10 Day Avg. Volume: 5,993,196
• 30 Day Avg. Volume: 2,829,509
• PEG Ratio: 1.00
• Price to Book (P/B): -22.40
• Price to Sales (P/S): 0.88
• P/FCF Ratio: 11.12
• Enterprise Value/Market Cap: 1.57
• Enterprise Value/Revenue: 2.43
• Enterprise Value/Gross Profit: 6.61
• Enterprise Value/Ebitda: 12.83
• 1Y Price Target: $14.33
• Price Target Upside: -0.69% Downside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 0.94
• Revenue Forecast (FY): $3.21B

• Rating: 64 Neutral
• Price Target: $15.00 ▲(3.95% Upside)

AMRX scores as moderate overall: technical momentum is strong and the earnings call featured raised guidance, but underlying financial profitability remains thin and valuation is a major headwind due to the extremely high P/E. Recent events are mixed, with interest savings offset by opioid settlement obligations.

Positive Factors

Biosimilars and Specialty Pipeline

A focused push into biosimilars and specialty launches (targeting six biosimilars by 2027 and multiple new specialty products) creates durable higher-margin revenue streams, diversifies reliance on commoditized generics, and positions the company to capture structural demand in biologics over several years.

Gross Margin and Revenue Stability

Healthy gross margins near 37% and steady top-line growth indicate efficient manufacturing and pricing power in core generics and specialty lines. This durable cost structure supports reinvestment in R&D and capacity, buffering profitability through pricing and input-cost cycles over the medium term.

Refinancing and Lower Interest Costs

Term loan repricing and extended maturities reduce recurring interest expense and improve liquidity profile. Lower cash interest (approx $11M annually) and extended maturities materially improve financial flexibility, enabling more stable capital allocation to R&D, product launches, or targeted M&A over multiple years.

Negative Factors

Low Net Profitability and ROE

Extremely low net margin and muted ROE signal limited ability to convert revenue into shareholder returns. Over time this constrains retained earnings available for reinvestment, reduces capacity to fund organic growth or buybacks, and leaves the company vulnerable to margin compression in cyclical periods.

Weak Free Cash Flow Growth

Negative free cash flow growth despite decent operating cash conversion indicates pressure on the company’s ability to expand investment or deleverage. Sustained FCF decline can limit long-term capital expenditure, R&D funding and make it harder to absorb one-time structural costs without raising external capital.

Opioid Settlement Obligations

A binding nationwide opioid settlement creates multi-year cash and product delivery obligations that materially affect available resources. Over the ten-year term these payments and product commitments reduce financial flexibility and compete with investments in pipeline commercialization and capacity expansion.

Amneal Pharmaceuticals Business Overview & Revenue Model

Company Description

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

How the Company Makes Money

Amneal Pharmaceuticals generates revenue primarily through the sale of generic and specialty pharmaceutical products. Its key revenue streams include the commercialization of generic drugs, which are sold at competitive prices to pharmacies, wholesalers, and healthcare providers. The company also earns revenue from specialty products that often entail higher margins compared to generic offerings, particularly in therapeutic areas that require more complex formulations. Additionally, Amneal benefits from strategic partnerships and collaborations with other pharmaceutical companies, which can enhance its product offerings and expand market reach. The company’s commitment to research and development allows it to continuously innovate and bring new products to market, contributing to long-term revenue growth.

Amneal Pharmaceuticals Financial Statement Overview

Summary

Steady sales and solid gross margin (36.76%) support operating stability, but overall profitability is weak (net margin 0.20%, ROE 5.06%). Cash generation is decent, yet free cash flow growth is negative (-6.73%), keeping the financial profile only moderate.

Income Statement

Amneal Pharmaceuticals shows a modest revenue growth rate of 2.88% in the TTM, indicating steady sales performance. The gross profit margin is healthy at 36.76%, reflecting efficient production and cost management. However, the net profit margin is low at 0.20%, suggesting challenges in translating revenue into profit. The EBIT and EBITDA margins are moderate at 10.74% and 18.93%, respectively, indicating reasonable operational efficiency but room for improvement in profitability.

Balance Sheet

The company's debt-to-equity ratio has improved significantly to 0.15 in the TTM, demonstrating a reduction in leverage and improved financial stability. However, the return on equity is low at 5.06%, indicating limited profitability from shareholders' investments. The equity ratio stands at 22.78%, suggesting a moderate level of financial stability but potential vulnerability to financial fluctuations.

Cash Flow

Operating cash flow is strong with a coverage ratio of 0.38, indicating good cash generation relative to net income. However, free cash flow growth is negative at -6.73%, highlighting challenges in maintaining cash flow growth. The free cash flow to net income ratio is 0.75, suggesting that a significant portion of earnings is converted to free cash flow, but there is room for improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.93B	2.79B	2.39B	2.21B	2.09B	1.99B
Gross Profit	1.08B	1.02B	863.87M	791.46M	768.97M	628.39M
EBITDA	555.65M	439.77M	500.78M	440.21M	401.10M	345.61M
Net Income	5.90M	-116.89M	-83.99M	-129.99M	10.62M	91.06M
Balance Sheet
Total Assets	3.60B	3.50B	3.47B	3.80B	3.94B	4.01B
Cash, Cash Equivalents and Short-Term Investments	201.25M	112.42M	93.74M	27.80M	247.79M	343.07M
Total Debt	2.69B	2.59B	2.75B	2.85B	2.88B	3.00B
Total Liabilities	3.71B	3.55B	3.41B	3.59B	3.57B	3.65B
Stockholders Equity	-109.46M	-109.27M	19.78M	298.42M	360.34M	303.27M
Cash Flow
Free Cash Flow	244.82M	220.11M	276.39M	-25.50M	194.09M	317.16M
Operating Cash Flow	327.75M	295.10M	345.58M	65.10M	241.82M	379.00M
Investing Cash Flow	-82.87M	-63.00M	-69.19M	-174.31M	-194.18M	-317.55M
Financing Cash Flow	-82.61M	-211.79M	-212.57M	-106.62M	-138.12M	131.81M

Amneal Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.43
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMRX, the sentiment is Positive. The current price of 14.43 is above the 20-day moving average (MA) of 13.64, above the 50-day MA of 12.94, and above the 200-day MA of 9.98, indicating a bullish trend. The MACD of 0.45 indicates Negative momentum. The RSI at 73.16 is Negative, neither overbought nor oversold. The STOCH value of 69.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMRX.

Amneal Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	79 Outperform	$1.31B	12.69	14.84%	―	-0.03%	-27.66%
ANIP	66 Neutral	$1.83B	49.98	7.83%	―	48.87%	―
AMRX	64 Neutral	$4.54B	1,040.14	―	―	9.50%	―
SUPN	55 Neutral	$2.81B	-144.87	-1.86%	―	4.54%	-130.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRGO	49 Neutral	$2.02B	―	-0.65%	8.48%	-2.55%	66.00%
ALVO	42 Neutral	$1.52B	21.67	―	―	55.38%	―

Amneal Pharmaceuticals Corporate Events

Amneal Pharmaceuticals Refinances Term Loans, Lowers Interest Costs

On February 2, 2026, Amneal Pharmaceuticals’ subsidiary, Amneal Pharmaceuticals LLC, and certain of its subsidiaries entered into a second amendment to their November 14, 2023 term loan credit agreement, refinancing and partially converting existing term loans into approximately $2.09 billion of new Amendment No. 2 Term Loans while keeping the August 1, 2032 maturity date unchanged. The repricing lowered the interest rate margins on the amended term loans by 50 basis points—to 2.00% over the base rate and 3.00% over the secured overnight financing rate—and introduced the ability to reprice the debt after August 2, 2026 without a prepayment premium, changes the company estimates will reduce its annual cash interest expense by about $11 million, strengthening its capital structure and lowering ongoing financing costs for stakeholders.

The most recent analyst rating on (AMRX) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.

Amneal Finalizes Nationwide Opioid Settlement Implementation Plan

On January 23, 2026, Amneal Pharmaceuticals said it would implement a nationwide opioids settlement after securing sufficient participation from all eligible state and territorial attorneys general and all subdivisions that had sued the company, with the agreement becoming effective on January 29, 2026. Under the settlement, Amneal will pay participating states and local governments $88.5 million and provide up to $177.4 million worth of naloxone nasal spray to treat opioid overdoses, with an option for settling parties to receive 25% of the naloxone’s value in cash during the final four years of the ten-year payment term, potentially raising the total cash outlay to as much as $132.9 million and helping the company resolve a substantial majority of its opioid-related liabilities.

The most recent analyst rating on (AMRX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.

Amneal Pharmaceuticals Files Routine Regulation FD Disclosure Report

On January 13, 2026, Amneal Pharmaceuticals, Inc. filed a report under the Securities Exchange Act of 1934, formally executed on behalf of the company by Executive Vice President and Chief Financial Officer Anastasios Konidaris, who also serves as the principal financial and accounting officer. The filing, which incorporates financial disclosure from another section by reference, represents a routine but important procedural step in the company’s ongoing financial reporting and regulatory compliance obligations, underscoring the CFO’s central role in certifying Amneal’s public disclosures for investors and regulators.

The most recent analyst rating on (AMRX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.